Detailed Narrative
Commercial Inflection and Product Adoption
Stereotaxis has reached a commercial inflection point in Q2 FY26, driven by accelerating adoption of its expanded product offering. The launch of MAGIC in the U.S. following FDA approval has led to a multi-year high in recurring revenue and significant growth in robotic catheter revenue. Early feedback from physicians on MAGIC is highly encouraging, noting improved targeting, ablation effectiveness, and efficiency. The company is methodically working through hospital approvals and initial launches of robotic catheters across its U.S. and European installed base.
Supply Chain and Manufacturing Ramp-up
Robotic catheter sales remain supply constrained, with a backlog of orders exceeding current supply from contract manufacturer Asipka. The company is putting significant effort into ramping manufacturing and establishing supply redundancy. This progress supports expectations of sustained growth in catheter revenue, with an anticipated $1 million incremental step up in catheter revenue in each of the next two quarters, and further opportunities in 2027.
Synchrony System Launch and Market Opportunity
The Synchrony system received FDA clearance in Q2 FY26, with initial orders and shipments contributing to system revenue. Synchrony modernizes the interventional surgical suite with enhanced workflow, remote connectivity, and AI capabilities. While current contribution is modest, the market opportunity is large, extending to non-robotic operating rooms. The company expects over $1 million in Synchrony system revenue each quarter for the next few quarters and plans to increase sales efforts as the pipeline builds and manufacturing matures.
Genesis X Commercialization and X-ray Compatibility
Genesis X is critical for scaling robotic adoption by removing the historical requirement for specific modified X-rays. The company announced its first U.S. Genesis X purchase from an academic medical center, expected to be installed this fall with a non-modified X-ray. This installation will enable formal compatibility declaration with a major X-ray manufacturer. The European Genesis X installation is also back on track for year-end. Proving Genesis X's reliability and compatibility with various X-rays is key to a more aggressive commercial launch.
Robust Innovation Pipeline
Stereotaxis continues to advance a robust innovation pipeline across several categories. This includes a future generation of fully wireless, battery-operated, and mobile Genesis X robots, and an expanded portfolio of EP catheter innovations, with first human procedures for MAGIC and pulse field ablation expected by year-end. The company is also developing robotic systems and interventional devices for broader cardiology and neurointerventional fields, including the Imagine family of magnetic guide catheters and guide wires, and the recently acquired RoboCath system for endovascular device navigation.
Financial Outlook and Profitability Path
The company maintains a lean operating budget while managing multiple product launches and R&D efforts. Management is confident in advancing its strategy without significant investor dilution. They are internally modeling to reach cash flow profitability in the first half of 2027, driven by the ramp-up in recurring revenue, where the majority of incremental revenue flows to operating profit. Profits will be reinvested into the commercial organization to support accelerated growth.